BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26031770)

  • 1. Successful combined liver/kidney transplantation from a donor with Pompe disease.
    Halldorson J; Kazi Z; Mekeel K; Kuo A; Hassanein T; Loomba R; Austin S; Valasek MA; Kishnani P; Hemming AW
    Mol Genet Metab; 2015 Aug; 115(4):141-4. PubMed ID: 26031770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
    Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
    Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease.
    Preisler N; Laforet P; Madsen KL; Hansen RS; Lukacs Z; Ørngreen MC; Lacour A; Vissing J
    Mol Genet Metab; 2012 Nov; 107(3):462-8. PubMed ID: 22981821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into therapeutic options for Pompe disease.
    Richard E; Douillard-Guilloux G; Caillaud C
    IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe course of glycogen storage disease type II (Pompe's disease) without development of cardiomegalia.
    Ullrich K; Gröbe H; Korinthenberg R; von Bassewitz DB
    Pathol Res Pract; 1986 Oct; 181(5):627-32. PubMed ID: 2947052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.
    Higuchi T; Kawagoe S; Otsu M; Shimada Y; Kobayashi H; Hirayama R; Eto K; Ida H; Ohashi T; Nakauchi H; Eto Y
    Mol Genet Metab; 2014 May; 112(1):44-8. PubMed ID: 24642446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse.
    Fuller M; Duplock S; Turner C; Davey P; Brooks DA; Hopwood JJ; Meikle PJ
    Anal Biochem; 2012 Feb; 421(2):759-63. PubMed ID: 22239964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.
    Kroos M; Pomponio RJ; van Vliet L; Palmer RE; Phipps M; Van der Helm R; Halley D; Reuser A;
    Hum Mutat; 2008 Jun; 29(6):E13-26. PubMed ID: 18425781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients.
    Palermo AT; Palmer RE; So KS; Oba-Shinjo SM; Zhang M; Richards B; Madhiwalla ST; Finn PF; Hasegawa A; Ciociola KM; Pescatori M; McVie-Wylie AJ; Mattaliano RJ; Madden SL; Marie SK; Klinger KW; Pomponio RJ
    Mol Genet Metab; 2012 Jul; 106(3):287-300. PubMed ID: 22658377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-Onset Pompe Disease with Normal Creatine Kinase Levels: The Importance of Rheumatological Suspicion.
    Marotto D; Moschetti M; Lo Curto A; Spezzigu AM; Giacomarra M; Marsana EM; Zizzo C; Duro G; Colomba P
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).
    Montagnese F; Granata F; Musumeci O; Rodolico C; Mondello S; Barca E; Cucinotta M; Ciranni A; Longo M; Toscano A
    J Inherit Metab Dis; 2016 May; 39(3):391-398. PubMed ID: 26830551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.